Therapy News and Research

RSS

POZEN reports positive Phase 1 study results comparing PA32540 to clopidogrel for CVDs

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results today from a Phase 1 study comparing a dose-timing strategy of PA32540 and clopidogrel spaced 10 hours apart as compared to synchronous administration of enteric-coated (EC) omeprazole (40 mg), enteric-coated aspirin (81 mg) and clopidogrel.

15 Nov 2011

Stem cell injections within two weeks may not help in post heart attack recovery

University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chance-just not as they originally thought.

15 Nov 2011

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that results from a Phase II trial (CTN-2006) in Stage III non-small cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy and an 8-year update from a phase I/II trial have been published in the November issue of Clinical Cancer, the journal of the American Association for Cancer Research.

15 Nov 2011

Whole-body-vibration does not effectively boost bone density

Whole-body-vibration, a popular exercise which uses a vibrating platform, is sometimes advertised as being able to boost bone density. However, a one-year-study on healthy postmenopausal women has shown that it has no such effect.

15 Nov 2011

Researchers explore how design of chronic and acute pain trials might be improved

For chronic pain sufferers, a day can feel like a year and a year can feel like an eternity. With very few truly new therapies approved by the U.S. Food and Drug Administration for this condition since 2005, the outlook is far from bright.

15 Nov 2011

Experts discuss treatment as prevention at USAID-, World Bank-sponsored debate

In this post in the Center for Global Development's "Global Health Policy" blog, Amanda Glassman, director of Global Health Policy and a research fellow at the center, reports on last week's USAID- and World Bank-sponsored debate on treatment as prevention, "where debaters were asked to support or oppose the proposition that countries should spend the majority of flat or declining HIV prevention budgets on 'treatment as prevention,' building off the results of the HPTN 052 study which found a relative reduction of 89 percent in the total number of HIV-1 transmissions resulting from the early initiation of antiretroviral therapy.

15 Nov 2011

Kessler Foundation researchers to improve rehabilitation after stroke

Kessler Foundation received a $250,000 stroke research grant from the Wallerstein Foundation for Geriatric Life Improvement. Anna Barrett, MD, director of Stroke Rehabilitation Research at Kessler Foundation, will apply the funds to finding better ways to treat hidden disabilities that often complicate recovery after stroke.

15 Nov 2011

Lentigen, UH Case Medical Center initiate LG631 Phase I trial in glioblastoma

University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting toxicity of chemotherapy with Temodar.

15 Nov 2011

Scientists discover promising approaches for treatment of pain

Scientists are discovering promising approaches to treating pain, one of the most common and debilitating neurological complaints, according to research released today at Neuroscience 2011, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

15 Nov 2011

Mesoblast reports positive Revascor Phase 2 heart failure trial results

Regenerative medicine company Mesoblast Limited today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months.

15 Nov 2011

Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.

14 Nov 2011

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Drug makers Bayer AG and Johnson & Johnson’s new blood clot preventing drug can provide life-saving benefits at very low doses in patients who suffer from acute coronary syndrome finds a new clinical trial.

14 Nov 2011

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that it has participated in a U.S. $3 million financing round of Avraham Pharmaceuticals Ltd. together with Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others.

14 Nov 2011

Stem cell bandage human clinical trial for torn meniscal cartilage

The company behind a pioneering stem cell bandage, believed to be the world's first adult and autologous (patient's own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK's most successful entrepreneurs.

14 Nov 2011

Bone-marrow derived cells do not improve heart function after attack

NIH-funded trial shows that therapy with bone-marrow derived cells does not improve heart function after six months; future clinical benefits still possible.

14 Nov 2011

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

An oral anti-clotting drug, when added to standard medical treatment for acute coronary syndrome, lowered the risk of death, heart attack or stroke an average of 16 percent, according to research presented at the American Heart Association's Scientific Sessions.

14 Nov 2011

Cerulean to present positive CRLX101 progression-free survival time results at 2011 AACR-NCI-EORTC

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the presentation of clinical and non-clinical data on its lead product candidate, CRLX101, at the 2011 AACR-NCI-EORTC International Conference taking place from November 12-16 in San Francisco, California.

14 Nov 2011

SANUWAVE Health third quarter revenues decrease 42% to $161,678

SANUWAVE Health, Inc. today reported financial results for the three and nine months ended September 30, 2011.

14 Nov 2011

Demand for non-drug intervention for atrial fibrillation will remain, despite FDA PVAC decision

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the search for an improved method of treating atrial fibrillation (AF) will be unaffected by the recent mixed decision by the Food and Drug Administration (FDA) panel on Medtronic's phased radiofrequency (RF) pulmonary vein ablation catheter (PVAC).

From Medtronic 14 Nov 2011

American Shared Hospital Services third quarter revenue increases to $9,148,000

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the third quarter and first nine months of 2011.

From Elekta 14 Nov 2011

Therapy News and Research

POZEN reports positive Phase 1 study results comparing PA32540 to clopidogrel for CVDs

Stem cell injections within two weeks may not help in post heart attack recovery

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

Whole-body-vibration does not effectively boost bone density

Researchers explore how design of chronic and acute pain trials might be improved

Experts discuss treatment as prevention at USAID-, World Bank-sponsored debate

Kessler Foundation researchers to improve rehabilitation after stroke

Lentigen, UH Case Medical Center initiate LG631 Phase I trial in glioblastoma

Scientists discover promising approaches for treatment of pain

Mesoblast reports positive Revascor Phase 2 heart failure trial results

Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Stem cell bandage human clinical trial for torn meniscal cartilage

Bone-marrow derived cells do not improve heart function after attack

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

Cerulean to present positive CRLX101 progression-free survival time results at 2011 AACR-NCI-EORTC

SANUWAVE Health third quarter revenues decrease 42% to $161,678

Demand for non-drug intervention for atrial fibrillation will remain, despite FDA PVAC decision

American Shared Hospital Services third quarter revenue increases to $9,148,000

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News